Term
|
Definition
[recombinant DNA human growth hormone] -replacement therapy SE: hyperglycemia, neutralizing Ab, carpal tunnel, fatality with PWS, interact w/glucocorticoids, hypothyroidism |
|
|
Term
|
Definition
[GHRH analog] -reduce excess abdominal fat in HIV+ w/lipodystrophy -category X drug |
|
|
Term
|
Definition
[insulin like growth hormone] -children w/ IGF-1 deficiency, neutralizing Ab from GH treatment, or defective GH receptor SE: hypoglycemia (given w/small meals) |
|
|
Term
|
Definition
[DA2 agonist] -Tx for excess GH in acromegaly, hyperprolactinemia, PD -dec fasting and post-prandial glucose levels -oral, taken in morning SE: nausea, HA, orthostatic hypotension, fatigue |
|
|
Term
|
Definition
[somatostatin analog] -inhibits Ca2+ influx -2-3x daily -sulfonylurea overdose (blocks Ca2+ induced insulin release downstream) SE: bradycardia, conduction problems |
|
|
Term
|
Definition
[somatostatin analog] -dose once every 2 weeks SE: nausea, ab cramps |
|
|
Term
|
Definition
[somatostatin analog] -multiligand (blocks GH and ACTH) -cushing's disease SE: hyperglycemia, inc liver enzymes |
|
|
Term
|
Definition
[GH receptor antag] -opioids dec its effects SE: inc liver enzymes, flu-like symptoms |
|
|
Term
|
Definition
[LH and FSH-like cmpnds] -induce ovulation -multiple births SE: ovarian hyperstimulation syndrome (enlargement, ascites, hypovolumia) |
|
|
Term
|
Definition
-induce ovulation -in vitro fertilization SE: ovarian hyperstimulation syndrome (enlargement, ascites, hypovolumia) |
|
|
Term
|
Definition
-induce ovulation SE: ovarian hyperstimulation syndrome (enlargement, ascites, hypovolumia) |
|
|
Term
|
Definition
[LH -like activity secreted by placenta] -induce ovulation -multiple births SE: ovarian hyperstimulation syndrome (enlargement, ascites, hypovolumia) |
|
|
Term
|
Definition
-induces ovulation, oral agent* -blocks E2 receptors in hypothalamus -prevents normal feedback, inc LH and FSH release* SE: multiple births, hot flashes, visual disturbances |
|
|
Term
|
Definition
[GnRH agonist] -short t1/2 SE: HA, dizziness, hot flashes |
|
|
Term
|
Definition
[GnRH agonist] -continuous for cancer -pulsatile for infertility SE: HA, dizziness, hot flashes |
|
|
Term
Centrorelix, Granirelix, Degarelix |
|
Definition
[GnRH antagonist] -dec release of LH and FSH -for cancer, controlled ovarian hyperstimulation (in vitro fertilization), endometriosis* |
|
|
Term
|
Definition
-stimulate vasopressin R's and cause water retention -milk ejection, uterine smooth muscle contraction |
|
|
Term
|
Definition
[oxytocin antagonist] -preterm labor |
|
|
Term
|
Definition
[ADH antagonist] -tx for SIADH (impairs cAMP action) SE: nephrogenic diabetes insipidus, polyuria, nephrotoxic w/ pts in liver failure |
|
|
Term
|
Definition
[ADH] -short t1/2 SE: water intoxication, excessive vasoconstriction |
|
|
Term
|
Definition
[ADH analog] -long t1/2, less V1 side effects -tx nephrogenic diabetes insipidus, hemophilia A (releases factor VIII), trauma induced bleeding, pre-op SE: fluid retention, hyponatremia, seizures |
|
|
Term
|
Definition
[ADH receptor blocker] -blocks V1 and V2 -euvolemic or hypervolemic hyponatremia (inc free water excretion BUT doesn't inc Na excretion) -inhibits CYP3A4 |
|
|
Term
|
Definition
[ADH receptor blocker] -blocks V2 -PKD, euvolemic/hyperV hyponatremia, SIADH -inc Na quickly, causes ODS (osmotic demyelination syndrome) -can be used in CHF SE: liver toxicity |
|
|
Term
Amiodarone, iodinated contrast media, BB, corticosteroids |
|
Definition
[5'-deiodinase inhibitor: T4-->T3] -tx for hyperthyroidism |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
[hypothyroidism tx] -T4 and T3 |
|
|
Term
|
Definition
[hyperthyroidism tx] -suppresses TH release, dec iodide uptake |
|
|
Term
|
Definition
[hyperthyroidism tx] -contraindicated in pregnancy, delayed hypothyroidism |
|
|
Term
|
Definition
[hyperthyroidism tx] -inhibits peroxidase and 5'-deiodinase *(blocks syn of TH by interfering w/ incorporation of I into tyrosyl residues) -tx for alcoholic liver disease -takes 2-4 weeks to work* SE: skin rashes, altered taste/smell, agranulocytosis, aplastic anemia |
|
|
Term
|
Definition
[hyperthyroidism tx] -inhibits peroxidase only -longer t1/2 -crosses placenta |
|
|
Term
Cortisol, cortisone, prednisone, prenisolone, methylprednisolone |
|
Definition
[corticosteroids] -some Na+ retention |
|
|
Term
Triamcinolone, betamethasone, dexamethasone |
|
Definition
[corticosteroids] -NO Na+ retention -for CHF (bc don't want to retain H2O and Na+) |
|
|
Term
|
Definition
[adrenocortical antagonist: affects all 3] -inhibits conversion of cholesterol to prenenolone -"medical adrenectomy" SE: blurred vision, drowsiness |
|
|
Term
|
Definition
[adrenocortical antagonist: affects all 3] -inhibits side chain cleavage of cholesterol (steroid hormone syn) |
|
|
Term
|
Definition
[adrenocortical antagonist: affects gluco and mineralo] -inhibits 11-B hydroxylase -only one used in pregnancy* (sex steroids not affected!) |
|
|
Term
|
Definition
[adrenocortical antagonist: affects all 3] -blocks 17-alpha hydroxylase and 17,20 lyase -tx for prostate cancer -prodrug |
|
|
Term
|
Definition
[nonspecific adrenocortical antagonist: progestin and glucocorticoid] -termination of pregnancy, induce labor after fetal death (w/ misprostol) -dec endometrial blood supply, detach blastocyst (w/ methotrexate), softens cervix SE: prolongs QT, hypertension, heavy bleeding, nausea, ab pain |
|
|
Term
|
Definition
[mineralocorticoid antagonist] -primary aldosteronism, K+ sparing diuretic -nonselective: also affects androgen R's (competes w/DHT) -effect lasts 2-3 days after discontinuation |
|
|
Term
|
Definition
[mineralocorticoid antagonist] -selective -metabolized via CYP3A4 |
|
|
Term
|
Definition
[mineralocorticoid antagonist] -progestin -aldosterone and androgen R antag SE: may inc risk for blood clots |
|
|
Term
|
Definition
[selective progestin receptor modulator] -blocks/delays ovulation, must start within 120 hrs post sex -alters endometrium -metabolized via CYP3A4 |
|
|
Term
|
Definition
[SSRI] -reduces menopausal hot flashes |
|
|
Term
Gabapentin, Clonidine, exercise, soy |
|
Definition
-reduces menopausal hot flashes |
|
|
Term
Medroxyprogesterone acetate |
|
Definition
[progesterone] -added during the last part of the cycle |
|
|
Term
|
Definition
[estrogen-like compound] -reverses bone loss without affecting reproductive tissues |
|
|
Term
|
Definition
-synthetic steroid w/3 metabolites: 2 estrogen properties, 1 progesterone and androgen |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Raloxifene, tamoxifen, toremifene, droloxifene |
|
Definition
[selective estrogen receptor modulator/ SERM] -dec. LDL (no HDL effect) -estrogen blocker in breast and uterus (antagonist) -tx for osteoporosis (agonist) -DOES NOT reduce menopausal hot flashes SE: toremifine inc QT |
|
|
Term
|
Definition
[weak androgen, progestin, glucocorticoid activity] -tx. for endometriosis, fibrocystic breast disease (suppresses ovarian function via LH and FSH inhibition) SE: liver problems, jaundice (androgen like effects) |
|
|
Term
|
Definition
-stimulates uterine contraction --> labor -control postpartum bleeding -abortion |
|
|
Term
|
Definition
-suppresses uterine contractions -inhibits preterm labor |
|
|
Term
|
Definition
[uterine relaxant for preterm labor] -inhibits Ca2+ entry and Ach release (weakness, resp arrest) -crosses placenta |
|
|
Term
|
Definition
[uterine relaxant for preterm labor] -blocks Ca2+ entry into uterine smooth muscle |
|
|
Term
|
Definition
[uterine relaxant for preterm labor] -Beta-2 selective agonist relaxes smooth muscle |
|
|
Term
|
Definition
[uterine relaxant for preterm labor] -inhibits PG syn -premature closure of DA |
|
|
Term
|
Definition
[uterine relaxant for preterm labor] -dec expression of genes that encode contraction (proteins in myometrium) -for women w/ at least 1 spontaneous preterm birth |
|
|
Term
Dinoprostone, misoprostol |
|
Definition
[promote cervical ripening] -activates collagenase -causes cervix to shorten, soften, and dilate (use w/ oxytocin) |
|
|
Term
|
Definition
[5-alpha reductase inhibitor] -inhibits ONE isoenzyme in prostate -shorter t1/2 -tx for BPH, hirsutism, alopecia -metabolized in liver |
|
|
Term
|
Definition
[5-alpha reductase inhibitor] -inhibits TWO isoenzymes in prostate, skin, liver -longer t1/2 |
|
|
Term
|
Definition
[anti-andronergic, R inhibitor for prostate cancer] -blocks binding of DHT -short t1/2 SE: hepatotoxicity, fewer effects than using GHRH antags |
|
|
Term
|
Definition
[anti-andronergic, R inhibitor for prostate cancer] -analog of flutamide but more selective -once a day |
|
|
Term
|
Definition
[anti-andronergic, R inhibitor for prostate cancer] -progestin -competitive antag of DHT |
|
|
Term
Insulin aspart, glulisine, Lispro |
|
Definition
[Synthetic insulin: ultra short] -onset 10-15 mins, duration 3-5 hrs (glulisine pregnancy category C) |
|
|
Term
|
Definition
[Synthetic insulin: intermediate] -onset 1-2 hrs, duration 10-14 hrs -only insulin that can be combined w/ others in the same syringe (draw up shorter acting first) |
|
|
Term
|
Definition
[Synthetic insulin: long] -onset 1-3 hrs, duration 14-23 hrs -bound to albumin |
|
|
Term
|
Definition
[Synthetic insulin: intermediate] -onset 1-4 hrs, duration 16-28 hrs -pH 4 neutralized and forms microprecipitates |
|
|
Term
|
Definition
[Synthetic insulin: ultra long] -duration >24 hrs -no peak activity -3x week |
|
|
Term
Tolbutamide, Tolazamide, Chlorpropamide |
|
Definition
[1st generation sulfonyureas] -metabolized in liver SE: disulfuram effects w/alcohol, hypoglycemia, weight gain
tolbutamide, tolazamide --> short chlorpropamide --> long |
|
|
Term
Glyburide, Glipizide, Glimepiride |
|
Definition
[2nd generation sulfonyureas] -metabolized in liver SE: hypoglycemia, weight gain |
|
|
Term
|
Definition
[sulfonylurea overdose- 2nd line drug] -ATP dependent K+ channel opener |
|
|
Term
|
Definition
[Meglitinide] -bind ATP dep K+ channels, short acting -vary amount needed by caloric intake SE: hypoglycemia |
|
|
Term
|
Definition
[Meglitinide] -bind ATP dep K+ channels (more selective), shorter acting |
|
|
Term
|
Definition
[Biguanide] -dec. glucose production, inc glucose uptake, dec insulin resistance -also tx for POS, ovarian cancer SE: GI effects (diarrhea), contraindicated w/kidney impairment, lactic acidosis |
|
|
Term
|
Definition
-inc. insulin sensitivity, inc glucose transporters by PPAR gamma SE: heart failure, worsen macular edema, inc risk of osteoporosis, liver tox, weight gain |
|
|
Term
|
Definition
-inc. insulin sensitivity, inc glucose transporters by PPAR gamma -some effect on PPAR alpha (dec TGs) -weak CYP3A4 inducer SE: bladder cancer, inc risk of osteoporosis, liver tox, weight gain |
|
|
Term
|
Definition
[Glucosidase inhibitor] -dec postprandial hyperglycemia -not much systemic absorption -given w/ each meal SE: gas, ab bloating |
|
|
Term
|
Definition
[Glucosidase inhibitor] -dec postprandial hyperglycemia -some systemic absorption |
|
|
Term
|
Definition
[Incretin hormone/ GLP-1 receptor agonist] -binds alpha cells --> dec hepatic glucose production in postprandial state -slows gastric emptying, satiety -subcutaneous or injection (not oral) SE: hypoglycemia, N/V, diarrhea, fetal abnormalities |
|
|
Term
|
Definition
[Incretin hormone/ GLP-1 analog] -once daily SE: thyroid tumors |
|
|
Term
|
Definition
[DPP-4 inhibitor] -oral, pregnancy category B -renal excretion -tablets may not dissolve completely SE: hypoglycemia |
|
|
Term
|
Definition
[DPP-4 inhibitor] -oral, pregnancy category B -half metabolized via CYP3A4 SE: hypoglycemia |
|
|
Term
|
Definition
[DPP-4 inhibitor] -oral, pregnancy category B -metabolized via CYP3A4, excreted unchanged in urine SE: hypoglycemia |
|
|
Term
|
Definition
[DPP-4 inhibitor] -oral, pregnancy category B -metabolized via CYP3A4, excreted unchanged in urine -once a day SE: hypoglycemia |
|
|
Term
|
Definition
[SGLT2 inhibitor] -lowers renal threshold for glucose -once a day SE: CV risk |
|
|
Term
|
Definition
[synthetic analog of human amylin] -delay gastric emptying, inhibit glucagon release -injected SE: hypoglycemia, dec, appetite, nausea |
|
|
Term
|
Definition
[bile resin] -inc incretin (GLP-1) secretion |
|
|